

Press Release

Global Pharma business in line with Guidance

Bangalore, July 25, 2013 Strides Arcolab (BSE: 532531, NSE: STAR) today announced its financial results for the Quarter ended June 30, 2013.

Highlights

Source: Management Accounts

Global Pharma

- Consolidated Pharma Revenues in H1 '13 at Rs.464 Crores with an EBITDA of Rs.101 Crores, impacted by an Exchange Loss of Rs.15 Crores (EBITDA Margin of 22%)
- Adjusted for Exchange Loss, H1'13 EBITDA at Rs.116 Crores, EBITDA Margin of 25%
- Pharma business EBITDA in line with guidance for 2013 (Revenue guided at Rs. 1000 crores with an EBITDA of Rs. 200 Crores)
- Q2'13 Consolidated Pharma Revenues at Rs.228 Crores with an EBITDA of Rs.41 Crores, impacted by an Exchange Loss of Rs.15 Crores (EBITDA Margin of 18%)
- Q2'13 Consolidated Pharma EBITDA grew by 30% (Rs.41 Crores in Q2 2013 against Rs.31 Crores in Q2 2012)

Biotech

- The design phase of the customized biotech facility at Bio-Xcell ecosystem, Malaysia is progressing and ground breaking scheduled for Q4'13.
- Product development progressing as per schedule for commercialization in early 2015

Pharma Regulatory Update

- 46 filings as on date with USFDA with 18 pending approvals
- Received WHO prequalification for Artemether+Lumifantrine (AL)
- Expects 2-3 key approvals during H2 '13

"We are pleased with our performance which is in line with our guided EBITDA and Revenues. With recent product approvals, we expect to deliver a strong second half in our pharmaceutical business," said Arun Kumar, Vice Chairman and Group CEO, Strides Arcolab Limited.

Standalone Financials

(Rupees in Crores)

	H1 '13	H1 '12	Growth %
Revenues	376	347	8%
EBITDA	85	59	44%
PBT	30	(48)	100+%
PAT	34	(48)	100+%
EPS	Rs.5.72	(Rs.8.21)	100+%

(Rupees in Crores)

	Q2 '13	Q2 '12	Growth %
Revenues	183	213	-14%
EBITDA	38	41	-7%
PBT	2	(20)	100+%
PAT	2	(20)	100+%
EPS	Rs.0.37	(Rs.3.39)	100+%

Source: unaudited standalone financials

Note: Management has opted to report standalone financials, which captures the Pharma business. Management opted out of reporting consolidated financials as the Agila business is in transition consequent to the sale of Agila business to Mylan Inc., as announced in February 2013.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India, that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides</u></p> <p>Dr. T.S. Rangan, Group CFO +91 80 6784 0115</p> <p><u>Investors:</u></p> <p>Mr. Kannan. N: +91 98450 54745 Mr. Vikesh Kumar +91 80 6784 0827</p>	<p><u>PR Consultancy</u></p> <p>Weber Shandwick</p> <p>Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com</p> <p>Mahesh Nair: +91 98803 76648 MNair@webershandwick.com</p>
---	--